Japan · Delayed Price · Currency is JPY Daiichi Sankyo Company Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and core operating profit grew strongly in FY 2025, led by oncology, despite one-time expenses reducing operating profit. The new five-year plan targets over JPY 3 trillion revenue by FY 2030, with continued investment in oncology and innovative drug technologies.
-
Operating profit forecast for FY 2025 was cut by JPY 106 billion due to temporary expenses from revised ADC supply plans and CMO compensation. The company is shifting to a risk-adjusted supply strategy, optimizing in-house and CMO roles, and maintaining its dividend outlook.
-
Revenue rose 12.1% year-over-year, driven by strong oncology sales, especially ENHERTU and DATROWAY, with core operating profit up 8.8%. Full-year guidance is unchanged, but DATROWAY’s forecast was raised due to higher demand. Key oncology trials and regulatory decisions are expected in the coming year.
-
Significant growth was achieved through a strategic shift to oncology, led by ENHERTU and DATROWAY, with robust financial performance and global expansion. The company is advancing its ADC platform, expanding indications, and investing in next-generation technologies for sustained growth.
-
Q2 FY2025 saw a 10.5% revenue increase, led by strong oncology sales, but core operating profit declined due to higher costs and inventory write-downs. The FY2025 revenue forecast was raised, with oncology drugs Enhertu and Datroway driving growth, while American Regent faced headwinds from competition and generics.
-
Revenue grew 8.8% year-over-year, driven by strong oncology sales, especially ENHERTU and DATROWAY, with operating profit up 32.1%. The company raised its DATROWAY sales forecast and reaffirmed its DOE target, while monitoring U.S. tariffs and advancing R&D in oncology.
Fiscal Year 2025
-
The event highlighted robust growth in the oncology pipeline, with multiple new approvals and strong sales for key ADCs, especially Enhertu and Datroway. Manufacturing capacity is expanding globally, and new research platforms—including next-generation ADCs and immuno-oncology assets—are advancing. The company aims for sustainable growth with a new midterm plan and ongoing innovation.
-
Sustainability management is driven by investment in human capital, science, and patient-centricity, with a focus on global talent, innovation, and robust governance. The upcoming five-year plan and 2035 vision will integrate ESG, double materiality, and strategies for post-Enhertu growth.
-
Multiple phase III trials showed ENHERTU and Dato-DXd significantly improve outcomes in high-risk breast and ovarian cancers, with favorable safety and potential to set new standards of care. Accelerated approval strategies are underway, and DS-3939 is advancing in multiple tumor types, especially lung cancer.
-
I-DXd demonstrated robust efficacy and manageable safety in relapsed ES-SCLC, including patients with brain metastases and those previously treated with platinum or T-cell engagers. The program is advancing rapidly with breakthrough therapy designation and ongoing pivotal trials, aiming for broad applicability and differentiation through a favorable safety profile.
-
Significant clinical advances were reported for ENHERTU and Dato-DXd in breast, gastric, and lung cancers, with robust efficacy and manageable safety. Biomarker-driven strategies are being integrated to optimize patient selection and increase trial success, with several pivotal readouts expected in 2025.
-
Revenue and profit surged in FY2024, led by strong global sales of Enhertu and milestone income from partnerships. FY2025 targets include JPY 2 trillion in revenue, higher dividends, and expanded share buybacks, while R&D investment remains robust and agile amid tariff and FX uncertainties.
-
Ambitious growth is driven by expanding indications for Enhertu and Datopotamab deruxtecan, with multiple pivotal trial readouts and launches expected to triple the eligible patient pool by 2026. Strong commercial execution, educational initiatives, and strategic alliances underpin robust sales growth and market penetration.
-
Q3 FY2024 saw strong revenue and profit growth, led by ENHERTU's global expansion and new approvals. FY2024 and FY2025 guidance remains robust despite DATROWAY delays, with mainstay products expected to offset shortfalls.
-
Revenue and operating profit are set for double-digit growth, driven by global expansion and strong ADC sales. ENHERTU and Datroway lead a robust pipeline, with new indications, digital pathology advances, and major investments in manufacturing and shareholder returns.
-
Q2 FY2024 saw revenue rise 21.5% year-on-year to JPY 882.7 billion, with core operating profit up 74.8% and net income up 51.2%. Upward revisions to FY2024 guidance reflect strong sales of Enhertu and Lixiana, FX tailwinds, and strategic alliances, despite regulatory and reimbursement uncertainties.
Fiscal Year 2024
-
Sustainability efforts focus on global growth, innovation, and human capital, with ongoing challenges in emissions reduction and gender diversity. Leadership development, board diversity, and transparent compensation are prioritized, while strategic partnerships and new research hubs drive R&D. The company is enhancing talent pipelines and preparing for its next midterm business plan.
-
Major advances in the DXd ADC pipeline include ENHERTU's expanded efficacy, Dato-DXd's regulatory progress in EGFR-mutated NSCLC, and robust clinical trial activity across oncology. Manufacturing capacity is being scaled globally to meet rising demand, while digital pathology and precision medicine are driving biomarker innovation and patient selection.
-
ASCO 2024 highlights showcased significant advances in breast and lung cancer, with T-DXd demonstrating strong efficacy and safety in HER2-low and ultra-low breast cancer, and Dato-DXd showing promise in NSCLC. The pipeline remains competitive, with ongoing pivotal trials and a focus on operational excellence.